Gastric UltrasoundNCT06567873
Gastric Ultrasound Assessment for Patients Taking Cannabis
An observational study of Gastric Ultrasound and Point of Care Ultrasound, run by Hospital for Special Surgery, New York at 1 site in United States.
Trial summary
The aim of this study is to perform bedside gastric point of care ultrasound (POCUS) exams to assess the gastric volume and content (clear liquids vs solid food) perioperatively in patients who report cannabis use. Read more about this study
- Who is it for?
- Ages 18 to 99 years
- Conditions the study is for
- Gastric Ultrasound, Point of Care Ultrasound, Cannabis Use
- What is being tested?
- Gastric Ultrasound Exam
- How many people
- 40 participants
- Where
- 1 siteUnited States
- Study dates
- 9 May 2025to 14 Oct 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 99 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study population will be comprised of patients scheduled for surgery at HSS who meet the following inclusion criteria and none of the exclusion criteria.
Who may be able to join
- Any patient reporting preoperative cannabis usage within 1 month of surgery date
Who cannot join
- Patient refusal to participate
- Patient with gastric bypass or any other gastric surgery
- Large hiatal hernia
- Patients with large ascites
- Patients on peritoneal dialysis
- Emergency surgery
Show all 14Show fewer
- Pre-existing diagnosis of gastroparesis
- Parkinson's disease
- Diabetes
- Currently taking metformin
- Chronic kidney disease stage 3 or higher
- Creatinine ≥ 1.2
- Esophageal surgery
- Currently taking GLP1 agonist medication
Trial locations and contacts
1 site in 1 country.
United States1 site
Hospital for Special Surgery
New York, New York, 10021
About this study
Official title: Assessment of Preoperative Gastric Content With Ultrasound in Patients Reporting Cannabis Use
The aim of this study is to perform bedside gastric point of care ultrasound (POCUS) exams to assess the gastric volume and content (clear liquids vs solid food) perioperatively in patients who report cannabis use.
Read the detailed description
Cannabis use in the United States has continued to increase in recent years, particularly in the adult population. Ease of access through legalization paired with improved public perception has contributed to the uptick in cannabis use. The subset of cannabis users suffering from pain who present for surgery pose a risk for perioperative aspiration due to the slowing of gastric motility due to cannabis use. There is currently no adapted NPO guideline to account for cannabis use.
Gastric Ultrasound (GUS) can be used as a bedside tool for assessing a patient's stomach contents and risk of aspiration. GUS can identify whether a patient's stomach is empty or filled with clear liquid, thick liquid, or solid food. The volume of the stomach can be accurately calculated if there is clear liquid content. A full stomach is categorized as those with solid or thick liquid content or with clear liquid measuring more than 1.5 ml/kg body weight. As GUS is noninvasive and does not pose risk to patients, it is a useful tool assessing aspiration risk in the preoperative period.
- Conditions
- Gastric Ultrasound, Point of Care Ultrasound, Cannabis Use
- Being tested
- Gastric Ultrasound Exam
- Keywords
- cannabis, gastric ultrasound
- Medical subject headings
- Marijuana Abuse
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Gastric Ultrasound ExamOther
A gastric ultrasound is a simple, fast, non-invasive bedside diagnostic test that provides a qualitative and quantitative assessment of gastric contents. There are no known risks of a gastric ultrasound exam.
| Study group | Role | What they receive |
|---|---|---|
| Cannabis Users | The cannabis user group will be comprised of patients who report preoperative cannabis use within 1 month of surgery date. This group will receive the ultrasound exam to assess stomach contents. Receives: Other: Gastric Ultrasound Exam |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of delayed gastric emptying
A full stomach on gastric ultrasound is defined by the presence of either solid food, thick liquids, or a specific volume (>1.5 ml/kg) of clear liquids on gastric ultrasound.
Measured: This will be measured pre-operatively in the holding room area.
Secondary outcomes (3)
Nothing by mouth (NPO) intervals
Measure the NPO interval after last solid food and liquid consumption
Measured: This will be measured pre-operatively in the holding room area.
Presence of gastric peristalsis
Gastric peristalsis will be graded as absent, slow, or normal on gastric ultrasound
Measured: This will be measured pre-operatively in the holding room area.
Time interval since last cannabis use
Measure the time from last cannabis consumption to the time the gastric ultrasound was performed
Measured: This will be measured pre-operatively in the holding room area.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Aug 2024
- Study start9 May 2025
- Primary completion13 Oct 2025
- Study completion14 Oct 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Gastric UltrasoundStudies of the same condition, open and under way.
- More trials run by Hospital for Special Surgery, New YorkThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 40 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hospital for Special Surgery, New York
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Oliver Panzer, MD, Principal investigator, Hospital for Special Surgery, New York
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06567873
- Sponsor's protocol ID
- 2024-1155
- Status last verified
- Nov 2025
- First submitted
- 20 Aug 2024
- Last updated
- 16 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
King DD, Stewart SA, Collins-Yoder A, Fleckner T, Price LL. Anesthesia for Patients Who Self-Report Cannabis (Marijuana) Use Before Esophagogastroduodenoscopy: A Retrospective Review. AANA J. 2021 Jun;89(3):205-212.
PubMed 34042571Cammarano CA, Villaluz JE. A Reason to Rethink Fasting Guidelines? Marijuana-Induced Gastroparesis and the Implications for Aspiration Risk in the Nil Per Os (NPO) Patient: A Case Report. Am J Case Rep. 2021 Nov 29;22:e934187. doi: 10.12659/AJCR.934187.
PubMed 34840324McCallum RW, Soykan I, Sridhar KR, Ricci DA, Lange RC, Plankey MW. Delta-9-tetrahydrocannabinol delays the gastric emptying of solid food in humans: a double-blind, randomized study. Aliment Pharmacol Ther. 1999 Jan;13(1):77-80. doi: 10.1046/j.1365-2036.1999.00441.x.
PubMed 9892882Esfandyari T, Camilleri M, Ferber I, Burton D, Baxter K, Zinsmeister AR. Effect of a cannabinoid agonist on gastrointestinal transit and postprandial satiation in healthy human subjects: a randomized, placebo-controlled study. Neurogastroenterol Motil. 2006 Sep;18(9):831-8. doi: 10.1111/j.1365-2982.2006.00834.x.
PubMed 16918762
Study at a glance
From the registry record, last updated by the sponsor on 16 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Assessment of Preoperative Gastric Content With Ultrasound in Patients Reporting Cannabis Use
- ClinicalTrials.gov ID
- NCT06567873
- Acronym / sponsor ID
- 2024-1155
- Conditions
- Gastric Ultrasound, Point of Care Ultrasound, Cannabis Use
- Keywords
- cannabis, gastric ultrasound
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 40 participants (actual)
- Lead sponsor
- Hospital for Special Surgery, New YorkUniversity, hospital or other
- Study start
- 9 May 2025 (actual)
- Primary completion
- 13 Oct 2025 (actual)
- Study completion
- 14 Oct 2025 (actual)
- First posted
- 23 Aug 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study is to perform bedside gastric point of care ultrasound (POCUS) exams to assess the gastric volume and content (clear liquids vs solid food) perioperatively in patients who report cannabis use.
Detailed description
Cannabis use in the United States has continued to increase in recent years, particularly in the adult population. Ease of access through legalization paired with improved public perception has contributed to the uptick in cannabis use. The subset of cannabis users suffering from pain who present for surgery pose a risk for perioperative aspiration due to the slowing of gastric motility due to cannabis use. There is currently no adapted NPO guideline to account for cannabis use.
Gastric Ultrasound (GUS) can be used as a bedside tool for assessing a patient's stomach contents and risk of aspiration. GUS can identify whether a patient's stomach is empty or filled with clear liquid, thick liquid, or solid food. The volume of the stomach can be accurately calculated if there is clear liquid content. A full stomach is categorized as those with solid or thick liquid content or with clear liquid measuring more than 1.5 ml/kg body weight. As GUS is noninvasive and does not pose risk to patients, it is a useful tool assessing aspiration risk in the preoperative period.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Cannabis Users | – | Other: Gastric Ultrasound ExamThe cannabis user group will be comprised of patients who report preoperative cannabis use within 1 month of surgery date. This group will receive the ultrasound exam to assess stomach contents. |
Who may qualify
- Ages
- 18 to 99 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study population will be comprised of patients scheduled for surgery at HSS who meet the following inclusion criteria and none of the exclusion criteria.
Key inclusion criteria (1 listed)
- Any patient reporting preoperative cannabis usage within 1 month of surgery date
Key exclusion criteria (14 listed)
- Patient refusal to participate
- Patient with gastric bypass or any other gastric surgery
- Large hiatal hernia
- Patients with large ascites
- Patients on peritoneal dialysis
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Gastric Ultrasound ExamA gastric ultrasound is a simple, fast, non-invasive bedside diagnostic test that provides a qualitative and quantitative assessment of gastric contents. There are no known risks of a gastric ultrasound exam. | Other | Cannabis Users |
Primary outcome
Incidence of delayed gastric emptying
Time frame: This will be measured pre-operatively in the holding room area.
A full stomach on gastric ultrasound is defined by the presence of either solid food, thick liquids, or a specific volume (>1.5 ml/kg) of clear liquids on gastric ultrasound.
3 secondary outcomes
Nothing by mouth (NPO) intervals
Time frame: This will be measured pre-operatively in the holding room area.
Presence of gastric peristalsis
Time frame: This will be measured pre-operatively in the holding room area.
Time interval since last cannabis use
Time frame: This will be measured pre-operatively in the holding room area.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Dec 2025.
- Background: PubMed 34042571King DD, Stewart SA, Collins-Yoder A, Fleckner T, Price LL. Anesthesia for Patients Who Self-Report Cannabis (Marijuana) Use Before Esophagogastroduodenoscopy: A Retrospective Review. AANA J. 2021 Jun;89(3):205-212.
- Background: PubMed 34840324Cammarano CA, Villaluz JE. A Reason to Rethink Fasting Guidelines? Marijuana-Induced Gastroparesis and the Implications for Aspiration Risk in the Nil Per Os (NPO) Patient: A Case Report. Am J Case Rep. 2021 Nov 29;22:e934187. doi: 10.12659/AJCR.934187.
- Background: PubMed 9892882McCallum RW, Soykan I, Sridhar KR, Ricci DA, Lange RC, Plankey MW. Delta-9-tetrahydrocannabinol delays the gastric emptying of solid food in humans: a double-blind, randomized study. Aliment Pharmacol Ther. 1999 Jan;13(1):77-80. doi: 10.1046/j.1365-2036.1999.00441.x.
- Background: PubMed 16918762Esfandyari T, Camilleri M, Ferber I, Burton D, Baxter K, Zinsmeister AR. Effect of a cannabinoid agonist on gastrointestinal transit and postprandial satiation in healthy human subjects: a randomized, placebo-controlled study. Neurogastroenterol Motil. 2006 Sep;18(9):831-8. doi: 10.1111/j.1365-2982.2006.00834.x.
- Individual participant dataSharing planned: No
Related trials for Gastric Ultrasound
RecruitingObservational study
Preoperative Gastric Ultrasound and Left Ventricular Function in Coronary Artery Bypass Surgery
Coronary Artery Disease, Left Ventricular Systolic Dysfunction
Not yet recruitingObservational study
Ultrasound Assessment Of Gastric Volume In Pregnant Women Undergoing Elective Cesarean Section
Gestational Diabetes Mellitus (GDM), Obstetric Anesthesia
Not yet recruitingObservational study
Preoperative Gastric Ultrasound and Anaesthetic Management in Patients Undergoing Coronary Artery Bypass Grafting
Preoperative Fasting, Pulmonary Aspiration During Anesthetic Induction
Not yet recruitingObservational study
Serum Estradiol and Endometrial Thickness After Bariatric Surgery in Postmenopausal Women With Obesity
Obesity, Morbid, Postmenopause
Not yet recruitingObservational study
Preoperative Gastric Volume and PONV in Pediatric Appendectomy Cases
Postoperative Nausea and Vomiting
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Oliver Panzer, MD principal investigator
Hospital for Special Surgery, New York
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Gastric Ultrasound and Point of Care Ultrasound, run by Hospital for Special Surgery, New York at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of delayed gastric emptying (time frame: This will be measured pre-operatively in the holding room area.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06567873, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Dec 2025.